Intercept Pharmaceuticals said Monday that the Food and Drug Administration rejected its drug to treat the fatty liver disease known as NASH — a decision that has obvious negative consequences for Intercept but could also raise concerns for other drugmakers developing similar treatments.

According to a statement from Intercept, FDA officials determined the “predicted benefit” of the company’s drug called obeticholic acid, or OCA, “does not sufficiently outweigh the potential risks” to support approval as a treatment for patients with NASH. The FDA further recommended that Intercept submit additional efficacy and safety data from its Phase 3 clinical trial.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • The NASH companies that will benefit from this are the ones that have clinical outcomes for the endpoints. Not just some measure of histology under the microscope.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy